5-Amino-1MQ

Small-molecule NNMT inhibitor discussed in preclinical metabolic/obesity contexts; human evidence is not established in the open literature.

research-chemicalmetabolicnnmt

Dosing model

FLATFixed dose (no body-weight scaling).

Min dose

—

Max dose

—

Rounding

—

Buy this ingredient ← Back

Stacks containing 5-Amino-1MQ

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.

Evidence

2 records

Diet-induced obesity / metabolic endpoints (preclinical)

Animal/preclinical models (as summarized in target-focused literature) • Preclinical summary (target-focused article)

Low

Literature discussing NNMT inhibition reports preclinical benefits on obesity-related outcomes; statements about 5-amino-1MQ efficacy are not equivalent to replicated human trials.

Dose: —

Citation: An et al., Experimental Neurology (2025) — NNMT as target; includes 5-amino-1MQ activity notes

NNMT inhibition and metabolic regulation (preclinical review)

Preclinical models; no human clinical trials identified • Review (preclinical; target-focused)

Low

A 2024 review summarizes NNMT as a therapeutic target for metabolic syndrome, noting preclinical evidence for NNMT inhibitors including 5-amino-1MQ; no human clinical trials have been published as of 2025.

Dose: —

Citation: Liu et al., Front Pharmacol (2024) — Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome

Forms

Small molecule (research)

Evidence primarily preclinical; translation uncertain.